Pure Global AI
NCT06105151Recruiting

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers
Vigonvita Life SciencesPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Schizophrenia
Drug/Device/Intervention
VV119(SAD)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vigonvita Life Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Oct 27, 2023
End date
Apr 01, 2024
Enrollment
70 participants
Primary outcome

Incidence of Treatment-Emergent Adverse Events,Cmax,area under the plasma concentration time curve from time zero to the last(AUC0-t),AUC0-∞,Tmax,t1/2,Apparent Clearance Rate（CL/F）,Vd/F,Ke,mean Resident Time from time zero to the last（MRT0-t）,mean Resident Time from time zero to infinity（MRT0-∞),AUC_%Extra,BP

Summary

This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food
 Effect (FE) study

ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06105151
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06105151 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vigonvita Life Sciences and is currently Recruiting. The study focuses on Schizophrenia. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.